Personalis Appoints Karin Eastham to Its Board of Directors
13 9월 2019 - 5:07AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced that it has appointed Karin Eastham as
an independent director to its Board of Directors. Ms. Eastham
brings more than 36 years of experience as both an executive and as
an independent director in the biotechnology industry, with deep
expertise in finance and operations. From May 2004 until her
retirement in September 2008, Ms. Eastham served as Executive Vice
President and Chief Operating Officer, and as a member of the Board
of Trustees, of the Burnham Institute for Medical Research (now
Sanford Burnham Prebys Medical Discovery Institute), a non-profit
corporation engaged in biomedical research.
Ms. Eastham currently serves as a Board member for Geron
Corporation, Veracyte, Inc. and Nektar Therapeutics. Previously,
she served on the public company boards of Illumina, Inc.,
MorphoSys AG, Trius Therapeutics, Inc., Amylin Pharmaceuticals,
Inc., Genoptix, Inc., Tercica, Inc. and SGX Pharmaceuticals,
Inc.
Ms. Eastham received both a B.S. in Accounting and an M.B.A. in
Finance from Indiana University.
“I am honored to join the Board of Personalis to support the
mission of transforming the development of next generation
therapeutics, driven by capturing the molecular data of each
patient’s cancer,” said Ms. Eastham.
"Personalis’ business leverages state-of-the-art genomics and
very large-scale data / analytics to help our customers develop the
next generation of cancer therapeutics,” said Jonathan MacQuitty,
Ph.D., Chairman of the Board of Personalis, Inc. “I’m delighted to
welcome Karin to the Board of Personalis. Her experience and
thinking will be invaluable to the company.”
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The company’s NeXT™ Platform is
designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190912005904/en/
Investor Relations Contact for Personalis: Caroline Corner
investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024